Bone Marrow Involvement of Epstein-Barr Virus-Positive Large B-Cell Lymphoma in a Patient with Angioimmunoblastic T-Cell Lymphoma

Lee, Taegeun; Park, Borae G.; You, Eunkyoung; Cho, Young Uk; Jang, Seongsoo; Lee, Sun Mi; Suh, Cheolwon; Park, Chan Jeoung

doi:10.3343/alm.2018.38.2.172

Cited by 4 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As per the previously reported cases (Zettl et al, 2002;Takahashi et al, 2010;Yang et al, 2012;Zhou et al, 2015;Chen et al, 2018;Lee et al, 2018), this patient carried EBV. We reasoned that the EBV protein signals (such as EBV-1 and LMP-1) may induce the secondary occurrence of B-cell lymphoma by promoting the proliferation of B cells (Dunleavy et al, 2007).…”

Section: Discussionsupporting

confidence: 85%

“…In general, the scattering and proliferation of Epstein-Barr virus (EBV) + large B cells are commonly seen in AITL and even cause the transformation to EBV + diffuse large B-cell lymphoma (DLBCL) (Huang et al, 2012;Szablewski et al, 2019). Until now, only dozens of cases with EBV + DLBCL secondary to AITL have been reported (Zettl et al, 2002;Takahashi et al, 2010;Yang et al, 2012;Zhou et al, 2015;Chen et al, 2018;Lee et al, 2018), and further exploration of the transformed mechanisms is essential. Tumor microenvironment (TME) and mutation landscape are unique in different kinds of diseases and are closely associated with the prognosis of AITL and DLBCL (Keane et al, 2013;Xu-Monette et al, 2019;Pritchett et al, 2021;Yu et al, 2021).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Case Report: Immune Microenvironment and Mutation Features in a Patient With Epstein–Barr Virus Positive Large B-Cell Lymphoma Secondary to Angioimmunoblastic T-Cell Lymphoma

Zhang

Cui

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

On rare occasions, secondary Epstein–Barr virus (EBV)-associated B-cell lymphoma can develop in patients with angioimmunoblastic T-cell lymphoma (AITL). Here, we describe the tumor microenvironment and mutation features of a patient with EBV + large B-cell lymphoma (LBCL) secondary to AITL. He was admitted to hospital due to a 1-year history of fever and enlarged right inguinal lymph nodes. A biopsy of the right inguinal lymph node demonstrated that numerous diffuse medium-sized atypical lymphocytes proliferated, together with increased extrafollicular follicular dendritic cell meshwork, and the lymphocytes expressed CD3, CD4, BCL6, CD10, PD-1, CXCL13, and Ki-67 (75%). Thus, a diagnosis of AITL was made. However, the disease progressed following treatment by CHOP regimen (cyclophosphamide, adriamycin, vincristine, and prednisone). Biopsy showed that most of the cells were positive for CD20 staining and IgH rearrangement. Analysis of 22 kinds of immune cells showed that the numbers of activated NK cells and activated memory T cells increased, while the T-follicular helper population decreased in the transformed sample. In addition, compared with the primary sample, RHOA (G17V) mutation was not detected, while JAK2 and TRIP12 gene mutations were detected in the transformed sample. Overall, we described the immune microenvironment and mutation features of a patient with EBV + LBCL secondary to AITL. This study will help us to understand the mechanisms by which AITL transforms to B-cell lymphoma.

show abstract

Section: Discussionsupporting

confidence: 85%

Section: Introductionmentioning

confidence: 99%

Case Report: Immune Microenvironment and Mutation Features in a Patient With Epstein–Barr Virus Positive Large B-Cell Lymphoma Secondary to Angioimmunoblastic T-Cell Lymphoma

Zhang

Cui

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

show abstract

Epstein–Barr virus positive diffuse large B‐cell lymphoma transformed into angioimmunoblastic T‐cell lymphoma after treatment

Wang

Gong

Jiang

et al. 2021

Clinical Case Reports

View full text Add to dashboard Cite

Angioimmunoblastic T‐cell lymphoma (AITL) is the subtype of mature T‐cell non‐Hodgkin lymphoma. Compared with diffuse large B‐cell lymphoma (DLBCL), AITL patients are frequently accompanied with Epstein–Barr virus (EBV) infection. To date, there is no report on the subsequent development of AITL in patients with EBV‐positive DLBCL. We performed a rare case of EBV‐positive AITL developing one year after initial diagnosis of EBV‐positive DLBCL. The patient showed poor response to the chemotherapy regimen, and poor survival.

show abstract

Systematic review about etiologic association to the leukoerythroblastic reaction

Calvache

Faulhaber

2020

Int J Lab Hematology

View full text Add to dashboard Cite

Background and purpose Leukoerythroblastic reaction (LER) is characterized by the presence of immature erythroid cells and myeloid precursors (metamyelocytes, myelocytes, promyelocytes, myeloblasts, and blasts) as well as, exclusively in myelofibrotic disorders, teardrop cells in the peripheral blood (J Pathol Bacteriol, 42, 1936, 541; Semaine Med, 22, 1902, 373). Research on how to interpret LER and its meaning in clinical practice is scarce, and there is no consensus on the diagnostic criteria. We summarize the current evidence with the aim of clarifying the knowledge on this subject. Methods We conducted a comprehensive search of the PubMed‐MEDLINE, EMBASE and ELSEVIER databases, the Cochrane Library, Google Scholar, and medical journals to identify relevant papers. Results Our search identified 425 papers, of which, 35 (11 trials and 24 case reports) ultimately met the inclusion criteria. These showed two principal groups of diseases associated with leukoerythroblastosis (LEB), corresponding to solid and hematological malignancies. The other etiologies, in order of frequency, were hemolytic diseases, infection, and others, while hemorrhage was only reported in the trials group. Conclusion The literature on LER is scarce and heterogeneous. The etiological factors of LER are diverse, and its presence in malignant disease is an indicator of disease progression and an adverse prognosis suggesting poor survival. In those cases where LER had neither hematological nor solid neoplasms, its manifestation, prognosis and its impact on our daily clinical practice are unknown.

show abstract

Bone Marrow Involvement of Epstein-Barr Virus-Positive Large B-Cell Lymphoma in a Patient with Angioimmunoblastic T-Cell Lymphoma

Cited by 4 publications

References 9 publications

Case Report: Immune Microenvironment and Mutation Features in a Patient With Epstein–Barr Virus Positive Large B-Cell Lymphoma Secondary to Angioimmunoblastic T-Cell Lymphoma

Case Report: Immune Microenvironment and Mutation Features in a Patient With Epstein–Barr Virus Positive Large B-Cell Lymphoma Secondary to Angioimmunoblastic T-Cell Lymphoma

Epstein–Barr virus positive diffuse large B‐cell lymphoma transformed into angioimmunoblastic T‐cell lymphoma after treatment

Systematic review about etiologic association to the leukoerythroblastic reaction

Contact Info

Product

Resources

About